CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Robinson Pharma

Since 1989 Robinson Pharma, Inc. (RPI) has served domestic and international marketers of vitamins and dietary supplements. From its humble beginnings as a contract packager, RPI has grown to become a significant entity in the dietary supplement industry

Proacta

Proacta is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSPEQ

BioSPEQ is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Haemacure Corporation

Clearside Biomedical

Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.